Transient cutaneous adenoviral gene therapy with human host defense peptide hCAP-18/LL-37 is effective for the treatment of burn wound infections

Jacobsen, Frank; Mittler, D.; Hirsch, Tobias; Gerhards, A.; Lehnhardt, Marcus; Voß, B.; Steinau, Hans-Ulrich; Steinstraesser, Lars

doi:10.1038/sj.gt.3302568

Cited by 88 publications

(67 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cytotoxic effects of the adenoviral vector were observed for HFB after 10 days and HaCaT after 30 days. Reporter gene expression in vivo was significantly higher in burned skin compared with unburned skin (P = 0,004 biological half-life (19,(22)(23)(24). New concepts and therapeutic strategies to improve current wound care are needed.…”

Section: O L M E D 1 2 ( 9 -1 0 ) 1 9 9 -2 0 7 S E P T E M B E R mentioning

confidence: 99%

Adenoviral Gene Delivery to Primary Human Cutaneous Cells and Burn Wounds

Hirsch

Peter

Dubin

et al. 2006

Mol Med

View full text Add to dashboard Cite

Section: O L M E D 1 2 ( 9 -1 0 ) 1 9 9 -2 0 7 S E P T E M B E R mentioning

confidence: 99%

Adenoviral Gene Delivery to Primary Human Cutaneous Cells and Burn Wounds

Hirsch

Peter

Dubin

et al. 2006

Mol Med

View full text Add to dashboard Cite

“…We demonstrated a bactericidal effect of LL-37 in a rat animal model following transient adenoviral gene therapy to P. aeruginosa-infected burn wounds (148).…”

Section: Host Defense Peptides In Woundsmentioning

confidence: 99%

Host Defense Peptides in Wound Healing

Steinstraesser

Koehler

Jacobsen

et al. 2008

Mol Med

141

112

View full text Add to dashboard Cite

Host defense peptides are effector molecules of the innate immune system. They show broad antimicrobial action against gram-positive and -negative bacteria, and they likely play a key role in activating and mediating the innate as well as adaptive immune response in infection and inflammation. These features make them of high interest for wound healing research. Nonhealing and infected wounds are a major problem in patient care and health care spending. Increasing infection rates, growing bacterial resistance to common antibiotics, and the lack of effective therapeutic options for the treatment of problematic wounds emphasize the need for new approaches in therapy and pathophysiologic understanding. This review focuses on the current knowledge of host defense peptides affecting wound healing and infection. We discuss the current data and highlight the potential future developments in this field of research.

show abstract

“…21 In a rat model, skin wounded by thermal injury has been transfected using human cathelicidin and proven significantly more effective than the administration of the synthetic host defense peptide. 22 A similar study using a human b-defensin-3 (HBD-3) plasmid construct has demonstrated significant antimicrobial activity in patients when transfected skin ulcers were analyzed. 23 Biopsies from transplanted epidermal sheets showed 2.5-times higher levels of HBD-3 transcripts than those of control skin.…”

Section: Suitable Animal Models Have Demonstrated Proof Of Concept Fomentioning

confidence: 99%

Gene therapy progress and prospects: the skin – easily accessible, but still far away

Hengge

2006

Gene Ther

View full text Add to dashboard Cite

Significant progress has been made in corrective gene therapy of inherited skin diseases. This includes advances in vector technology, targeted gene expression, gene replacement, and the availability of appropriate animal models for a variety of candidate diseases. In addition, an increased understanding of the uptake and trafficking mechanisms inside keratinocytes has evolved. Topical application facilitates DNA vaccination through the skin, albeit clinical benefits have not yet materialized. However, the translation into clinical trials has only been partially mastered. The latter and the control of immune responses represent challenges for the research community.

show abstract

Transient cutaneous adenoviral gene therapy with human host defense peptide hCAP-18/LL-37 is effective for the treatment of burn wound infections

Cited by 88 publications

References 50 publications

Adenoviral Gene Delivery to Primary Human Cutaneous Cells and Burn Wounds

Adenoviral Gene Delivery to Primary Human Cutaneous Cells and Burn Wounds

Host Defense Peptides in Wound Healing

Gene therapy progress and prospects: the skin – easily accessible, but still far away

Contact Info

Product

Resources

About